Core Viewpoint - 康龙化成 has signed a placement agreement with Goldman Sachs (Asia) LLC and HSBC Hong Kong to issue 58,440,762 new H-shares at a price of HKD 22.82 per share, aiming to raise approximately HKD 1,333.6 million [1][2] Group 1 - The placement shares represent approximately 19.86% of the existing issued H-shares and 3.30% of the total issued shares as of the announcement date [1] - If fully subscribed, the net proceeds from the placement are expected to be around HKD 1,318.7 million, with a net price per share of approximately HKD 22.56 [2] - The company plans to allocate about 70% of the net proceeds for project construction to enhance laboratory service facilities and production capacity [2] Group 2 - Approximately 10% of the proceeds will be used to repay bank loans and other borrowings to optimize the company's capital structure [2] - About 20% of the funds will be allocated to supplement working capital and other general corporate purposes [2] - The board believes that this issuance will strengthen the company's financial position, capture industry opportunities, and support capacity investment and business expansion [2]

董事会认为，公司是一家领先的全流程一体化医药研发生产服务平台，业务遍及全球，致力于进一步巩 固服务能力，加速全球药物创新。进行本次发行事项将进一步加强本公司的资金实力，把握行业机遇， 助力产能投入与业务拓展。本次发行也将为公司引入国际优质机构投资者群体，进一步扩大股东基础， 并有望显着增强H股的交易流动性，有助于加强公司的国际资本运作能力。另外，通过偿还部分现有债 务，公司的资本结构将得到进一步优化。此次发行将支持公司继续保持在医药研发服务领域的领先地 位，符合公司的长期发展战略。 配售股份数目分别占：(a)截至本公告日期现有已发行H股总数及现有已发行股份总数约19.86%及 3.30%；及(b)假设于本公告日期至完成期间配售股份均获认购，且除公司发行配售股份外，已发行股份 总数无其他变动，则配售完成后，配售股份数目分别占经配售股份发行扩大的已发行H股总数及已发行 股份总数约16.57%及3.19%。 假设配售股份获全数认购，配售所得款项总额预期约为1,333.6百万港元。配售所得款项净额预期约为 1,318.7百万港元，每股配售股份的净价约为22.56港元，公司拟将所得款项净额用作以下用途：(1)约 70% ...